Cometriq 80mg tablets (Cabozantinib) | MHP
COMETRIQ 80MG
DESCRIPTION:
Cometriq 80mg is a prescription medicine required to treat people with medullary thyroid cancer (MTC) which has spread to other parts of the body known as metastatic MTC.Cometriq 80mg is highly protein bound and there is a hypothetical risk that it will displace combination with warfarin, so INR monitoring is recommended.
Cometriq 80mg is not known if using in children safe and effective.
INDICATION:
Cometriq 80mg is Indicated for following conditions;The treatment of Metastatic medullary thyroid cancer
The treatment of Advanced renal cell carcinoma (RCC) who have getting before anti-angiogenic therapy.
The treatment of Hepatocellular cancer who have previously received sorafenib.
MECHANISM OF ACTION:
Cabozantinib is also known as targeted therapy which aims and attach to the tyrosine kinase receptors and prohibits the activity of multiple tyrosine kinases, contains RET, MET, and VEGF on the surface of the cell.By connecting to these receptors, Cabozantinib stops important pathways which develop cell division.
 |
| COMETRIQ 80MG TABLETS |
PRODUCTS DEATIALS:
Brand :CometriqIngredients : Cabozantinib
Strength : 80mg
Manufactured : Exelixis.Inc
Package : 30 tablets
ADME:
Maximum plasma concentration is observed in 2-5 hoursHuman serum protein bounding of Cometriq is ≥ 99.7%
Mostly metabolized by CYP3A4 and minorly by CYP2C9.
The drug excreted mostly via feces 54 % and in urine 27% and half-life is 55 hours.
DOSAGE MANAGMENT:
Do not substitute Cometriq tablets with Cabozantinib capsules.The prescribed dose of Cometriq is 60 mg.
Administration Cometriq is without food.
Tell the patients don’t not havefood for at least 2 hours before and 1 hour after taking Cometriq.
Continue the treatment until patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Swallow Cometriq tablets whole. Do not crush Cometriq tablets.
PRECUATIONS:
• Interrupt the Cometriq 80mg in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.• Interrupt the Cometriq 80mg for patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.
• Check the patients for symptoms of perforations and fistulas, included abscess. discontinue Cometriq 80mg in patients who experience a perforation or a fistula.
• Avoid administration Cometriq 80mg to patients with a present history of patients with haemorrhage or haemoptysis.
• Advice pregnant women about possible risk to a foetus. Hence inform females of reproductive possible to use effective contraception during treatment with Cometriq 80mg and for 4 months after the last dose.
SIDE EFFECTS:
• GI perforations and fistulas• Thrombotic events
• Hypertension and hypertensive crisis
• Diarrhea
• Palmar-plantar erythrodysesthesia
• Haemorrhage
• Reversible posterior leukoencephalopathy syndrome
• Weight loss
• Decreased appetite
• Nausea
• Fatigue
• Oral pain
• Neutropenia
• Low platelets
• Taste changes
• Hair colour changes
• High blood pressure
• Low potassium
• Hair loss
• Dizziness
• Joint pain
• Swallowing trouble
• Muscle spasms
• Dyspepsia (indigestion)
• Skin redness
• Reduced sodium
DRUG INTERACTION:
Concurrent use of Cometriq with strong CYP3A4 inhibitor will have high the single dose plasma Cometriq 80mg exposure by 38%.Co administration of Cometriq with strong CYP3A4 inducers will decreased the single dose plasma Cometriq 80mg exposure by 77%
Interaction of Cometriq with MRP2 inhibitors may increase the exposure to Cometriq 80mg.
CONTAINDICATION:
The drug Cometriq 80mg is contraindicated to Hypersensitivity reaction in patients
PREGNANCY:
Pregnancy Category is D: Based on studies of animal and mechanism of action, Cometriq 80mg will cause risk to fetus when given to pregnant women.Avoid pregnancy while on treatment with cometriq 80mg.
LACTATION:
Advise the women not to breastfed to infants while on treatment with Cometriq 80mg drugs because of possible risk to the fetus.STORAGE:
Store the drug at 20°C to 25°CKeep away from the children resistances
Comments
Post a Comment